ArticleJCI insight2017
Dengue vaccine-induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies.
Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 40 citations in OpenAlex.
- From promise to pitfalls: immunological lessons from dengue vaccines and their implications.NPJ vaccines · 2026Review
- Challenges and Opportunities in the Development of Dengue Vaccines: A Comprehensive Review.Advanced biomedical research · 2026Review
- Glycans on non-structural protein 1 prevent premature T-cell mediated dengue virus clearance.EMBO molecular medicine · 2025Article
- Enhanced durability of a Zika virus self-amplifying RNA vaccine through combinatorial OX40 and 4-1BB agonism.JCI insight · 2025Article
- Dysregulated immune cell responses in severe dengue pathogenesis.Frontiers in immunology · 2025Review
- Exploring Dengue Infection in a Vaccinated Individual: Preliminary Molecular Diagnosis and Sequencing Insights.Viruses · 2024Article
- Zika virus T-cell based 704/DNA vaccine promotes protection from Zika virus infection in the absence of neutralizing antibodies.PLoS neglected tropical diseases · 2024Article
- Article
- Intermediate Levels of Pre-Existing Protective Antibody Allow Priming of Protective T Cell Immunity against Influenza.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Dengue in Pregnancy: A Southeast Asian Perspective.Tropical medicine and infectious disease · 2023Review
- Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses.Frontiers in immunology · 2023Article
- Infection order outweighs the role of CD4iScience · 2022Article
- Article
- Zika virus infection during pregnancy protects against secondary infection in the absence of CD8Virology · 2021Article
- A single-dose live attenuated chimeric vaccine candidate against Zika virus.NPJ vaccines · 2021Article
- Vaccines against COVID-19.Anaesthesia, critical care & pain medicine · 2020Article
- Conserved epitopes with high HLA-I population coverage are targets of CD8Scientific reports · 2020Article
- Japanese encephalitis virus-primed CD8+ T cells prevent antibody-dependent enhancement of Zika virus pathogenesis.The Journal of experimental medicine · 2020Article
- Cross-serotypically conserved epitope recommendations for a universal T cell-based dengue vaccine.PLoS neglected tropical diseases · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Declining levels of maternal antibodies were shown to sensitize infants born to dengue-immune mothers to severe disease during primary infection, through the process of antibody-dependent enhancement of infection (ADE). With the recent approval for human use of Sanofi-Pasteur's chimeric dengue vaccine CYD-TDV and several vaccine candidates in clinical development, the scenario of infants born to vaccinated mothers has become a reality. This raises 2 questions: will declining levels of maternal vaccine-induced antibodies cause ADE; and, will maternal antibodies interfere with vaccination efficacy in the infant? To address these questions, the above scenario was modeled in mice. Type I IFN-deficient female mice were immunized with live attenuated DENV2 PDK53, the core component of the tetravalent DENVax candidate currently under clinical development. Pups born to PDK53-immunized dams acquired maternal antibodies that strongly neutralized parental strain 16681, but not the heterologous DENV2 strain D2Y98P-PP1, and instead caused ADE during primary infection with this strain. Furthermore, pups failed to seroconvert after PDK53 vaccination, owing to maternal antibody interference. However, a cross-protective multifunctional CD8+ T cell response did develop. Thus, our work advocates for the development of dengue vaccine candidates that induce protective CD8+ T cells despite the presence of enhancing, interfering maternal antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.